Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile

Sci Adv. 2021 Feb 12;7(7):eabe6855. doi: 10.1126/sciadv.abe6855. Print 2021 Feb.


Chile has one of the worst numbers worldwide in terms of SARS-CoV-2 positive cases and COVID-19-related deaths per million inhabitants; thus, characterization of neutralizing antibody (NAb) responses in the general population is critical to understanding of immunity at the local level. Given our inability to perform massive classical neutralization assays due to the scarce availability of BSL-3 facilities in the country, we developed and fully characterized an HIV-based SARS-CoV-2 pseudotype, which was used in a 96-well plate format to investigate NAb responses in samples from individuals exposed to SARS-CoV-2 or treated with convalescent plasma. We also identified samples with decreased or enhanced neutralization activity against the D614G spike variant compared with the wild type, indicating the relevance of this variant in host immunity. The data presented here represent the first insights into NAb responses in individuals from Chile, serving as a guide for future studies in the country.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Antibodies, Neutralizing / blood*
  • Antibodies, Viral / blood*
  • COVID-19 Serological Testing*
  • COVID-19* / blood
  • COVID-19* / genetics
  • Chile
  • Chlorocebus aethiops
  • Female
  • HEK293 Cells
  • Humans
  • Male
  • Mutation, Missense*
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / metabolism
  • Spike Glycoprotein, Coronavirus* / blood
  • Spike Glycoprotein, Coronavirus* / genetics
  • Vero Cells


  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2